Please assess the completion status of the following clinical trial:

Trial Title: Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
The following are general criteria; more specific criteria are included in the study protocol:~Inclusion Criteria:~* NYHA Class IIIB/IV (refer to Appendix IV for definitions)~* Left ventricular ejection fraction (LVEF) ≤ 25%~* Not currently listed for heart transplantation, and not planned in next 12 months~* On optimal medical management~* Limited functional status as demonstrated by 6MWT \<300 meters~* At least:~  * One hospitalization for HF in last 12 months or~ * At least 2 unscheduled emergency room or infusion clinic visits (may include intravenous diuretic therapy, etc.) for HF in last 12 months~Exclusion Criteria:~* Presence of mechanical aortic or mitral valve, including planned conversion to bioprosthesis~* Platelet count \< 100,000/mi within 48 prior to enrollment~* Any inotrope use within 30 days prior to enrollment~* Inability to perform 6MWT for any reason~* Any condition, other than heart failure, that could limit survival to less than 2 years~* History of cardiac or other organ transplant~* Existence of any ongoing mechanical circulatory support (including intraaortic balloon pump, temporary circulatory support devices, etc.) at the time of enrollment~* Presence of active, uncontrolled, systemic infection~* History of an unresolved stroke within 90 days prior to enrollment, or a history of cerebral vascular disease with significant (\> 80%)extracranial stenosis~* Contraindication to anticoagulation/antiplatelet therapy~* CRT or CRT-D within 3 months prior to enrollment~* Coronary revascularization (e.g. CABG, PCI) within 3 months prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- HM II (HeartMate II LVAD) (Type: None): Subjects who elect to, and receive HM II LVAD therapy at baseline
- OMM (Optimal Medical Management) (Type: None): Subjects who elect to remain on optimal medical management

Based on this trial design, predict the completion outcome and termination type (if applicable).